339 related articles for article (PubMed ID: 25837922)
1. Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats.
Liu YS; Huang ZW; Wang L; Liu XX; Wang YM; Zhang Y; Zhang M
J Pharmacol Sci; 2015 Mar; 127(3):260-74. PubMed ID: 25837922
[TBL] [Abstract][Full Text] [Related]
2. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
Yamada H; Tanaka A; Kusunose K; Amano R; Matsuhisa M; Daida H; Ito M; Tsutsui H; Nanasato M; Kamiya H; Bando YK; Odawara M; Yoshida H; Murohara T; Sata M; Node K;
Cardiovasc Diabetol; 2017 May; 16(1):63. PubMed ID: 28490337
[TBL] [Abstract][Full Text] [Related]
3. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
Oe H; Nakamura K; Kihara H; Shimada K; Fukuda S; Takagi T; Miyoshi T; Hirata K; Yoshikawa J; Ito H;
Cardiovasc Diabetol; 2015 Jun; 14():83. PubMed ID: 26084668
[TBL] [Abstract][Full Text] [Related]
4. DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes.
Connelly KA; Zhang Y; Advani A; Advani SL; Thai K; Yuen DA; Gilbert RE
Cardiovasc Ther; 2013 Oct; 31(5):259-67. PubMed ID: 22963483
[TBL] [Abstract][Full Text] [Related]
5. Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits.
Zhang X; Zhang Z; Yang Y; Suo Y; Liu R; Qiu J; Zhao Y; Jiang N; Liu C; Tse G; Li G; Liu T
Cardiovasc Diabetol; 2018 Dec; 17(1):160. PubMed ID: 30591063
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase.
Tang ST; Su H; Zhang Q; Tang HQ; Wang CJ; Zhou Q; Wei W; Zhu HQ; Wang Y
Int J Mol Med; 2016 Jun; 37(6):1558-66. PubMed ID: 27122056
[TBL] [Abstract][Full Text] [Related]
7. Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking.
Ramírez E; Picatoste B; González-Bris A; Oteo M; Cruz F; Caro-Vadillo A; Egido J; Tuñón J; Morcillo MA; Lorenzo Ó
Cardiovasc Diabetol; 2018 Jan; 17(1):12. PubMed ID: 29325553
[TBL] [Abstract][Full Text] [Related]
8. Sitagliptin attenuates myocardial apoptosis via activating LKB-1/AMPK/Akt pathway and suppressing the activity of GSK-3β and p38α/MAPK in a rat model of diabetic cardiomyopathy.
Al-Damry NT; Attia HA; Al-Rasheed NM; Al-Rasheed NM; Mohamad RA; Al-Amin MA; Dizmiri N; Atteya M
Biomed Pharmacother; 2018 Nov; 107():347-358. PubMed ID: 30099338
[TBL] [Abstract][Full Text] [Related]
9. Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease.
Beraldo JI; Benetti A; Borges-Júnior FA; Arruda-Junior DF; Martins FL; Jensen L; Dariolli R; Shimizu MH; Seguro AC; Luchi WM; Girardi ACC
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31010001
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats.
Karabulut S; Coskun ZM; Bolkent S
Pharmacol Rep; 2015 Oct; 67(5):846-53. PubMed ID: 26398375
[TBL] [Abstract][Full Text] [Related]
11. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
McCormick LM; Kydd AC; Read PA; Ring LS; Bond SJ; Hoole SP; Dutka DP
Circ Cardiovasc Imaging; 2014 Mar; 7(2):274-81. PubMed ID: 24503784
[TBL] [Abstract][Full Text] [Related]
12. Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction.
Esposito G; Cappetta D; Russo R; Rivellino A; Ciuffreda LP; Roviezzo F; Piegari E; Berrino L; Rossi F; De Angelis A; Urbanek K
Br J Pharmacol; 2017 Nov; 174(22):4070-4086. PubMed ID: 27922176
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.
Gonçalves A; Marques C; Leal E; Ribeiro CF; Reis F; Ambrósio AF; Fernandes R
Biochim Biophys Acta; 2014 Sep; 1842(9):1454-63. PubMed ID: 24769045
[TBL] [Abstract][Full Text] [Related]
14. Reduction of cardiac and renal dysfunction by new inhibitor of DPP4 in diabetic rats.
Alves BEO; de Alencar AKN; Gamba LER; Trachez MM; da Silva JS; Araújo JSC; Montagnoli TL; Mendes LVP; Pimentel-Coelho PM; do M N Cunha V; Mendez-Otero R; Oliveira GMM; Lima LM; Barreiro EJ; Sudo RT; Zapata-Sudo G
Pharmacol Rep; 2019 Dec; 71(6):1190-1200. PubMed ID: 31669883
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic β-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers.
Fukui K; Kawahito H; Wakana N; Kikai M; Terada K; Yamamoto K; Irie D; Kato T; Miyagawa S; Yamada H
J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1001-9. PubMed ID: 26195265
[TBL] [Abstract][Full Text] [Related]
16. Sitagliptin Protects Cardiac Function by Reducing Nitroxidative Stress and Promoting Autophagy in Zucker Diabetic Fatty (ZDF) Rats.
Zhou Y; Wang H; Man F; Guo Z; Xu J; Yan W; Li J; Pan Q; Wang W
Cardiovasc Drugs Ther; 2018 Dec; 32(6):541-552. PubMed ID: 30328028
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes.
Monji A; Mitsui T; Bando YK; Aoyama M; Shigeta T; Murohara T
Am J Physiol Heart Circ Physiol; 2013 Aug; 305(3):H295-304. PubMed ID: 23709595
[TBL] [Abstract][Full Text] [Related]
18. Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure.
dos Santos L; Salles TA; Arruda-Junior DF; Campos LC; Pereira AC; Barreto AL; Antonio EL; Mansur AJ; Tucci PJ; Krieger JE; Girardi AC
Circ Heart Fail; 2013 Sep; 6(5):1029-38. PubMed ID: 23894014
[TBL] [Abstract][Full Text] [Related]
19. Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats.
Al-Rasheed NM; Al-Rasheed NM; Hasan IH; Al-Amin MA; Al-Ajmi HN; Mahmoud AM
Drug Des Devel Ther; 2016; 10():2095-107. PubMed ID: 27418808
[TBL] [Abstract][Full Text] [Related]
20. Sitagliptin for Type 2 diabetes: a 2015 update.
Lee M; Rhee MK
Expert Rev Cardiovasc Ther; 2015 Jun; 13(6):597-610. PubMed ID: 26000559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
